Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Reaffirmed by HC Wainwright

Iterum Therapeutics (NASDAQ:ITRMGet Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 289.61% from the company’s current price.

Iterum Therapeutics Trading Down 3.1 %

NASDAQ ITRM opened at $1.54 on Monday. The company’s 50-day simple moving average is $1.53 and its two-hundred day simple moving average is $1.38. The company has a debt-to-equity ratio of 3.63, a quick ratio of 2.35 and a current ratio of 2.35. The company has a market capitalization of $20.70 million, a price-to-earnings ratio of -0.52 and a beta of 2.36. Iterum Therapeutics has a one year low of $0.62 and a one year high of $2.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP acquired a new position in Iterum Therapeutics in the 3rd quarter worth about $101,000. Goldman Sachs Group Inc. purchased a new position in Iterum Therapeutics in the 2nd quarter valued at about $61,000. Finally, Renaissance Technologies LLC boosted its holdings in Iterum Therapeutics by 199.1% in the 2nd quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock worth $65,000 after buying an additional 215,200 shares during the last quarter. 9.21% of the stock is currently owned by hedge funds and other institutional investors.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Articles

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.